Search
Dianthus Therapeutics Inc
DNTHAdd to Watchlist
92.785USD
-5.565-5.66%
Market hours 09/23, 13:48（ET）
5.07BMarket Cap
LossP/E TTM
Dianthus Therapeutics Inc (DNTH) Stock Price Target & Forecast
Analyst Rating
Based on 17 analysts giving stock ratings to Dianthus Therapeutics Inc in the past month.
Buy
8 Strong Buy
9 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
139.357USD+43.95%
DNTH Analyst Recommendation Trends
In the current month, DNTH has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DNTH average Analyst price target in the last month is 139.357.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
8
8
8
8
9
8
7
7
9
9
8
8
8
8
8
8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17
17
16
16
17
16
15
15
DNTH Analyst Rating for Peer Comparison
Updated: Sep 22, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
11
14
3
0
0
28
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
7
7
1
1
21
Financial Forecasting
Based on analysts' estimates, DNTH EPS is projected to reach -0.966 in FY2026Q3, following reported EPS of -0.896 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.08
-1.07
-0.86
-0.97
-1.06
Actual
-1.43
-0.85
-0.90
--
--
Surprise
-32.98%
+20.71%
-4.49%
--
--
FAQs
What is Dianthus Therapeutics Inc's expected revenue for the next quarter?
Dianthus Therapeutics Inc's expected revenue is 425.00K.
What is Dianthus Therapeutics Inc's price target?
Analysts forecast that Dianthus Therapeutics Inc's price target is USD 139.36, with the highest forecast at USD 200.00 and the lowest forecast at USD 122.00.
How have Dianthus Therapeutics IncDNTH's recent earnings per share performed?
The market expectation was USD -0.90, while Dianthus Therapeutics IncDNTH's earnings per share (EPS) for the previous quarter was USD -0.85. EPS for the next quarter is expected at USD -0.97.
What is the analyst rating for Dianthus Therapeutics Inc?
Based on the ratings of Dianthus Therapeutics Inc's stock from 17 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.